Integrated Filing- Financial

Divi’s Laboratories has reported its standalone financial results for the quarter and nine months ended December 31, 2024. Revenue from operations reached ₹2,297 crore for the quarter and ₹6,662 crore year-to-date, reflecting significant growth compared to the previous year.

Profit after tax for the quarter stood at ₹594 crore, while for the nine-month period, it was ₹1,542 crore.

The company has commenced operations at its new Unit III project in Kakinada as of January 1, 2025, which may bolster future revenue prospects.

With robust earnings and operational expansion, investor sentiment could be positively influenced, presenting opportunities for growth in a dynamic pharmaceutical market.